EMD Serono Newsroom

To keep up with the latest news in real-time, subscribe to our email alerts, and follow us on Twitter, Facebook and LinkedIn. If you are a reporter and have questions about the company, please contact us

Latest News

 

Feb 16, 2019

Not intended for UK-based media JAVELIN Renal 101 shows significant improvement in progression-free survival with a hazard ratio of 0.69 in patients regardless of PD-L1 expression US FDA has...

Feb 11, 2019

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for BAVENCIO® (avelumab) in combination with INLYTA® (axitinib)* for patients with advanced renal cell carcinoma (RCC). The application has been given a target action date in June 2019.

Feb 6, 2019

Merck KGaA, Darmstadt, Germany investing $70 million in U.S. Research & Development Hub Expansion of R&D footprint to accelerate science and innovation in Oncology,...

Feb 5, 2019

Eight high priority immuno-oncology clinical development studies ongoing or expected to commence in 2019, including studies in non-small cell lung and biliary tract cancers Merck KGaA, Darmstadt,...

  All Press Releases